Grant: Idea to Innovation
University of Toronto
$125,000.00
Development of an automated system for blastocyst biopsy with minimal invasiveness in IVF clinics
FY 2022-23
Summary
One in six Canadian couples struggles with infertility. In clinical in vitro fertilization (IVF), ~60% embryos that proceed to transfer end in pregnancy loss caused by chromosomal aneuploidy. To select euploid embryos with high implantation potential, embryo biopsy is widely used in IVF to collect a few trophectoderm cells (which will develop into the placenta) from Day 5/6 embryos for preimplantation genetic testing (PGT). Present embryo biopsy is a complicated manual operation and demands high skills for cell manipulation. It requires long training time, but still suffers from large damage to the embryo and collected cells, which reduces the embryo's reproductive potential and PGT accuracy. This I2I project aims to develop a system for automated embryo biopsy with minimal damage. The system is able to automatically manipulate embryos with minimal cell deformation, determine collected cell number, and separate target cells along cell connections/junctions without impairing them. This automated biopsy system will eliminate operator subjectivity and inconsistency in manual biopsy, minimize damage to both embryos and collected cells, which will greatly improve the embryo's reproductive potential and PGT accuracy. The commercialization of this automated embryo biopsy technology will standardize the practice of embryo biopsy in IVF clinics and help clinics meet the rapidly increasing demand for embryo biopsy worldwide. In addition, this technology will help reduce the heavy psychological and financial burden on patients/families who experience repeated IVF treatment failures. The high-quality embryos selected through automated, minimally invasive biopsy will help improve the health of offspring, resulting in higher quality of life and lower cost to the healthcare system over the child's life.
Program
Idea to Innovation
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
570995-2022
Name nom
Sun, Yu Y
Department département
Mechanical and Industrial Engineering
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2022
Competition year année de concours
2022
Award amount
125000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
2109
Research subject group en
Mechanical engineering
Research subject group fr
Génie mécanique
Research subject en
Mechanical systems and instrumentation
Research subject fr
Instrumentation et systèmes mécaniques
Installment
inst:1
Partie
1
Nb partie
1
Application title
Development of an automated system for blastocyst biopsy with minimal invasiveness in IVF clinics
Application summary
One in six Canadian couples struggles with infertility. In clinical in vitro fertilization (IVF), ~60% embryos that proceed to transfer end in pregnancy loss caused by chromosomal aneuploidy. To select euploid embryos with high implantation potential, embryo biopsy is widely used in IVF to collect a few trophectoderm cells (which will develop into the placenta) from Day 5/6 embryos for preimplantation genetic testing (PGT). Present embryo biopsy is a complicated manual operation and demands high skills for cell manipulation. It requires long training time, but still suffers from large damage to the embryo and collected cells, which reduces the embryo's reproductive potential and PGT accuracy. This I2I project aims to develop a system for automated embryo biopsy with minimal damage. The system is able to automatically manipulate embryos with minimal cell deformation, determine collected cell number, and separate target cells along cell connections/junctions without impairing them. This automated biopsy system will eliminate operator subjectivity and inconsistency in manual biopsy, minimize damage to both embryos and collected cells, which will greatly improve the embryo's reproductive potential and PGT accuracy. The commercialization of this automated embryo biopsy technology will standardize the practice of embryo biopsy in IVF clinics and help clinics meet the rapidly increasing demand for embryo biopsy worldwide. In addition, this technology will help reduce the heavy psychological and financial burden on patients/families who experience repeated IVF treatment failures. The high-quality embryos selected through automated, minimally invasive biopsy will help improve the health of offspring, resulting in higher quality of life and lower cost to the healthcare system over the child's life.